Delivery Order SPE2DB24D2101-SPE2DB25FKJWS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.93 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. The contract was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and employs firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order valued at $32,838.00 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price contract was competitively awarded without set-asides and is scheduled for completion by June 20, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $4,109.19 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. This firm fixed-price, non-set-aside contract was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction executed under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $38,677.92 to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken,...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKJWSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,771.21 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by April 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor vehicle valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical supplier to federal medical procurement programs supporting military and veteran healthcare systems. The underlying IDC enables the company to deliver a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to customers including the Defense Health Agency and U.S. Coast Guard. Actemra is a biologic immunosuppressant used in the treatment of rheumatoid arthritis and other inflammatory conditions, making this delivery order representative of the company's role in supplying specialized pharmaceutical commodities to support military healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 4/24/25 |